Cizzle Biotechnology Holdings PLC Market Cap ($55.46K)
Market Cap & Net Worth: Cizzle Biotechnology Holdings PLC (CIZ)
Cizzle Biotechnology Holdings PLC market cap. Cizzle Biotechnology Holdings PLC (LSE:CIZ) has a market capitalization of $55.46K (GBX455.85 Million) as of November 8, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31656 globally and #1186 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cizzle Biotechnology Holdings PLC's stock price GBX1.15 by its total outstanding shares 396391773 (396.39 Million). Also see how efficiently does Cizzle Biotechnology Holdings PLC generate cash for how efficiently the company converts equity into cash flow.
Cizzle Biotechnology Holdings PLC Market Cap History (2015–2026)
Cizzle Biotechnology Holdings PLC market cap history from 2015 to 2026. Data shows change from $31.29 Million to $55.46K (-46.45% CAGR). Check latest Cizzle Biotechnology Holdings PLC stock price today for real-time trading data and today's change.
Cizzle Biotechnology Holdings PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cizzle Biotechnology Holdings PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CIZ net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.18x
Cizzle Biotechnology Holdings PLC's market cap is 3.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $31.29 Million | $6.90 Million | -$2.77 Million | 4.53x | N/A |
| 2016 | $20.61 Million | $5.32 Million | -$159.38 | 3.88x | N/A |
| 2017 | $11.41 Million | $4.55 Million | -$118.20 | 2.51x | N/A |
| 2018 | $235.60K | $74.00K | -$2.06 Million | 3.18x | N/A |
Competitor Companies of CIZ by Market Capitalization
Companies near Cizzle Biotechnology Holdings PLC in the global market cap rankings as of November 8, 2026. Also see Cizzle Biotechnology Holdings PLC assets under control for a full breakdown of the balance sheet.
Key companies related to Cizzle Biotechnology Holdings PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Cizzle Biotechnology Holdings PLC (2015–2026)
Market capitalization of Cizzle Biotechnology Holdings PLC from 2015 to today. Between 2015 and today, Cizzle Biotechnology Holdings PLC's market cap moved from $31.29 Million to $ 55.46K, with a yearly change of -46.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX55.46K | -25.81% |
| 2025 | GBX74.76K | 0.00% |
| 2024 | GBX74.76K | -20.51% |
| 2023 | GBX94.05K | +34.48% |
| 2022 | GBX69.93K | -51.67% |
| 2021 | GBX144.69K | -73.91% |
| 2019 | GBX554.64K | +135.41% |
| 2018 | GBX235.60K | -97.94% |
| 2017 | GBX11.41 Million | -44.64% |
| 2016 | GBX20.61 Million | -34.12% |
| 2015 | GBX31.29 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Cizzle Biotechnology Holdings PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $55.46K USD |
| MoneyControl | $55.46K USD |
| MarketWatch | $55.46K USD |
| marketcap.company | $55.46K USD |
| Reuters | $55.46K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings … Read more